Ipca Laboratories Limited (NSE:IPCALAB)
1,524.40
-48.00 (-3.05%)
May 29, 2026, 3:29 PM IST
Ipca Laboratories Employees
Ipca Laboratories had 16,778 employees as of March 31, 2025. The number of employees decreased by 557 or -3.21% compared to the previous year.
Employees
16,778
Change (1Y)
-557
Growth (1Y)
-3.21%
Revenue / Employee
5.85M INR
Profits / Employee
680.13K INR
Market Cap
386.75B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 16,778 | -557 | -3.21% |
| Mar 31, 2024 | 17,335 | 1,168 | 7.22% |
| Mar 31, 2023 | 16,167 | 1,012 | 6.68% |
| Mar 31, 2022 | 15,155 | 581 | 3.99% |
| Mar 31, 2021 | 14,574 | 508 | 3.61% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aurobindo Pharma | 27,707 |
| Alkem Laboratories | 18,785 |
| Glenmark Pharmaceuticals | 15,800 |
| Ajanta Pharma | 9,628 |
| Emcure Pharmaceuticals | 6,731 |
| Laurus Labs | 6,167 |
| Piramal Pharma | 5,476 |
| Gland Pharma | 4,351 |
Ipca Laboratories News
- Just now - Ipca Laboratories Quarterly report: Q4 2026 - Filings
- 2 months ago - Top stocks to buy: Stock recommendations for March 30, 2026 week - check list - The Times of India
- 2 months ago - Top stocks to buy: Stock recommendations for March 23, 2026 week - check list - The Times of India
- 3 months ago - Ipca Laboratories Transcript: Q3 25/26 - Transcripts
- 3 months ago - Ipca Laboratories Quarterly report: Q3 2026 - Filings
- 3 months ago - Ipca Laboratories Q3 Results: Net profit jumps 31.5% YoY to Rs 326.27 crore, revenue up 6.55% - Business Upturn
- 4 months ago - Ipca Laboratories receives US FDA VAI status for Tarapur API facility - Business Upturn
- 6 months ago - This brokerage firm advises to Buy IPCA Labs shares and expects nearly 20% upside in stock price - Business Upturn